Thyrocare Technologies Ltd - 539871 - Announcement - Update
This is to update that two Centres of Nueclear Healthcare Limited, the wholly owned subsidiary of our company, situated at Surat and Baroda have been closed due to unfair business practices by the Franchisee. We are seeking legal remedies. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are forwarding copy of Presentation on Quarterly Results of our company for the quarter / nine months ended 31-12-2019. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicized. Thyrocare Technologies Ltd - 539871 - Results - Financial Results - Quarter/9 Months Ended 31-12-2019
Our Board of Directors at their meeting today approved unaudited Financial Results (Stand-alone & Consolidated) for Quarter / 9 months ended 31-12-2019. The said results & Limited Review Reports are attached. Board decided to defer question of further dividend to next meeting. Board approved reappointment of Dr. A. Velumani as MD & CEO for a further period of 5 years from 01-04-2020, as recommended by the N & R Committee, on a remuneration of Rs. 1.5 crores p.a. but Dr. A. Velumani opted to receive a token remuneration of Re. 1/- per month, as opted for the previous tenure, too. Board approved reappointment of Mr. A. Sundararaju as ED & CFO for a further period of 5 years from 01-04-2020, as recommended by the N & R Committee & Audit Committee, on a remuneration of Rs. 0.75 crores p.a. but Mr. A. Sundararaju opted to receive the same remuneration of Re. 5 lakhs per month, as he was receiving in the previous tenure. Meeting commenced at 17.30 hours and ended at 19.30 hours. Thyrocare Technologies Ltd - 539871 - Outcome Of Board Meeting Held On 01-02-2020
Our Board of Directors at their meeting today approved unaudited Financial Results (Stand-alone & Consolidated) for Quarter / 9 months ended 31-12-2019. The said results & Limited Review Reports are attached. Board decided to defer question of further dividend to next meeting. Board approved reappointment of Dr. A. Velumani as MD & CEO for a further period of 5 years from 01-04-2020, as recommended by the N & R Committee, on a remuneration of Rs. 1.5 crores p.a. but Dr. A. Velumani opted to receive a token remuneration of Re. 1/- per month, as opted for the previous tenure, too. Board approved reappointment of Mr. A. Sundararaju as ED & CFO for a further period of 5 years from 01-04-2020, as recommended by the N & R Committee & Audit Committee, on a remuneration of Rs. 0.75 crores p.a. but Mr. A. Sundararaju opted to receive the same remuneration of Re. 5 lakhs per month, as he was receiving in the previous tenure. Meeting commenced at 17.30 hours and ended at 19.30 hours. Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for To Consider & Approve Unaudited Standalone & Consolidated Financial Results For The Quarter/9 Months Ended 31-12-2019, Payment Of Further Interim Dividend, If Any, And Reappointment Of Dr. A. Velumani As MD & CEO And Mr. A. Sundararaju As ED & CFO.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, February 01, 2020, at the Corporate Office of the Company, to inter alia, consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2019, payment of further interim dividend, if any, and reappointment of Dr. A. Velumani as Managing Director & CEO, and Mr. A. Sundararaju as Executive Director & CFO. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended December 31, 2019
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with effect from January 01, 2020, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter / nine months ended December 31, 2019. We request you to please take the same on record. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Company has introduced an ESOP Scheme under which 37,759 number of equity shares of face value of Rs. 10/- each have been allotted to 103 eligible employees who have exercised the Options granted to them under ESOP Scheme 2016, after getting in-principle and listing approval from both the Stock Exchanges i.e. National Stock Exchange of India Limited and BSE Limited. These shares shall rank pari passu with the existing equity shares of the Company in all respects. None of the Promoter Directors and Independent Directors was allotted shares under this scheme. With this allotment, the issued, subscribed and paid up equity capital of the Company stands increased as follows: Issued, Subscribed and Paid-up Equity Capital No. of shares Amount (Rs.) Before this issue 52,798,606 527,986,060.00 Shares now issued under ESOP 37,759 377,590.00 After this issue 52,836,365 528,363,650.00 Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of Sundaram Asset Management Company Limited would be having a meeting with us at 10.30 A.M. on Saturday, December 14, 2019 at the Corporate Office of the Company. Please note that this is subject to any last minute changes.